[Novel strategies for preventing viral hepatitis C recurrence after liver transplantation].
Hepatitis C virus (HCV) is a major cause of chronic liver disease. About 170 million people worldwide are chronically infected. No preventive or therapeutic vaccine is available. Current antiviral combinations based on pegylated interferon alpha (IFN-alpha) and ribavirin have limited efficacy, poor tolerability and high cost. End-stage liver disease due to chronic HCV infection is a leading indication for liver transplantation (LT). However, re-infection of the liver graft is inevitable, with a high risk of cirrhosis within 5 years. To infect the graft, circulating virions need to attach to and enter hepatocytes, via viral envelope glycoproteins E1-E2. E1-E2 can react with cell receptors despite the presence of neutralizing antibodies. [corrected] A better understanding of the early steps of viral attachment and escape from neutralizing antibodies could lead to novel antiviral strategies.
Stoll-Keller
Françoise
F
Institut de Virologie de la Faculté de Médecine et Unité INSERM 748, 3 rue Koeberlé, 67000 Strasbourg.
Fafi-Kremer
Samira
S
Wolf
Philippe
P
Doffoël
Michel
M
Baumert
Thomas
T
D000998:Antiviral Agents / Q000627:therapeutic use; D000939:Epitopes / Q000276:immunology; D016174:Hepacivirus / Q000187:drug effects / Q000235:genetics / Q000276:immunology / Q000502:physiology; D018937:Hepatitis C Antibodies / Q000276:immunology; D018936:Hepatitis C Antigens / Q000276:immunology; D019698:Hepatitis C, Chronic / Q000517:prevention & control*; D022781:Hepatocytes / Q000821:virology; D054884:Host-Pathogen Interactions; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects; D008103:Liver Cirrhosis / Q000209:etiology / Q000517:prevention & control; D016031:Liver Transplantation; D011183:Postoperative Complications / Q000517:prevention & control / Q000821:virology; D012008:Recurrence; D014774:Virulence; D053585:Virus Attachment / Q000187:drug effects; D053586:Virus Internalization / Q000187:drug effects; D014779:Virus Replication
D000998:Antiviral Agents; D000939:Epitopes; D018937:Hepatitis C Antibodies; D018936:Hepatitis C Antigens